Inflammasomes are multi-protein platforms that initiate innate immunity by recruitment and activation of Caspase-1. The NLRP1B inflammasome is activated upon direct cleavage by the anthrax lethal toxin protease. However, the mechanism by which cleavage results in NLRP1B activation is unknown. Here we find that cleavage results in proteasomemediated degradation of the N-terminal domains of NLRP1B, liberating a C-terminal fragment 5 that is a potent Caspase-1 activator. Proteasome-mediated degradation of NLRP1B is both necessary and sufficient for NLRP1B activation. Consistent with our new 'functional degradation' model, we identify IpaH7.8, a Shigella flexneri ubiquitin ligase secreted effector, as an enzyme that induces NLRP1B degradation and activation. Our results provide a unified mechanism for NLRP1B activation by diverse pathogen-encoded enzymatic activities. 10 One Sentence Summary: Two distinct pathogen enzymes activate an innate immune sensor called NLRP1B by a mechanism that requires proteasome-mediated degradation of NLRP1B.
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Main Text:
In animals, pathogens are generally recognized by germline-encoded innate immune receptors that bind directly to conserved pathogen-associated molecular patterns (PAMPs) such as bacterial lipopolysaccharide or flagellin (1) . Recognition of PAMPs permits robust self-nonself discrimination, but because PAMPs are found on harmless as well as pathogenic microbes, 5 PAMP receptors do not distinguish pathogens from non-pathogens. Plants also use germlineencoded receptors to detect PAMPs, but in addition, respond to infection by indirect detection of secreted pathogen enzymes called 'effectors' (2) . In this mode of recognition, called 'effectortriggered immunity', intracellular proteins of the nucleotide-binding domain leucine-rich repeat (NLR) superfamily sense effector-induced perturbation of host signaling pathways. Because 10 harmless microbes do not deliver effectors into host cells, effector-triggered immunity is inherently pathogen-specific. It has been proposed that animals may also detect pathogenencoded activities (3) (4) (5) (6) (7) (8) (9) , but there are relatively few examples of this mode of pathogen recognition that are understood in molecular detail.
We sought to determine how a particular mammalian NLR protein called NLRP1 senses 15 pathogen-encoded activities. NLRP1 is the founding member of a class of proteins that form inflammasomes (10), multi-protein platforms that initiate immune responses by recruiting and activating pro-inflammatory proteases, including Caspase-1 (CASP1) (11) (12) (13) . CASP1 cleaves and activates specific cytokines (interleukins-1β and -18) and a pore-forming protein called Gasdermin D, leading to a lytic host cell death called pyroptosis. In certain strains of mice and 20 rats, a specific NLRP1 family member called NLRP1B is activated via direct proteolysis of its N-terminus by the lethal factor (LF) protease secreted by Bacillus anthracis (14) (15) (16) (17) . Previous studies demonstrated that N-terminal proteolysis is sufficient to initiate NLRP1B inflammasome activation (15), but the molecular mechanism by which proteolysis activates NLRP1B has been elusive. 25 Similar to other NLRs, NLRP1B contains a nucleotide-binding domain and leucine-rich repeats (Fig. 1A) . However, NLRP1B also exhibits several unique features. First, the NLRP1B caspase activation and recruitment domain (CARD) is C-terminal instead of N-terminal, as in other NLRs. Second, NLRP1B is the only NLR that contains a function-to-find domain (FIIND). The FIIND constitutively undergoes an auto-proteolytic event, resulting in two separate 30 NLRP1B polypeptides that remain non-covalently associated with each other (18) (19) (20) . Mutations that abolish FIIND auto-processing block inflammasome activation (19, 20) , but it remains unclear why FIIND auto-processing is essential for NLRP1B function. Lastly, proteasome inhibitors specifically block NLRP1B inflammasome activation, but do not affect other inflammasomes or inhibit LF protease, suggesting the proteasome is specifically required for 35 activation of NLRP1B itself (21) (22) (23) (24) (25) .
Cleavage of NLRP1B by LF results in a loss of 44 amino acids from the N-terminus of NLRP1B, an event that correlates with its activation (14) (15) (16) (17) . We and others have previously proposed an 'auto-inhibition' model to explain NLRP1B activation (12, 26) . In this model, the N-terminus of NLRP1B functions as an auto-inhibitory domain that is lost after cleavage by LF. 40 The NLRP1B N-terminus might mediate auto-inhibition either through direct engagement with other NLRP1B domains in cis, or by binding to an inhibitory co-factor. A clear prediction of the auto-inhibition model is that sequences within the N-terminus should be required to prevent spontaneous inflammasome activation. To identify such sequences, we systematically mutated the NLRP1B N-terminus by replacing groups of three consecutive amino acids with alanines ( Fig. 1B) or by replacing groups of five sequential amino acids with a flexible GGSGG motif (Fig. 1C ). Each mutant was also engineered to contain an N-terminal TEV protease site to enable inducible NLRP1B cleavage and activation (15, 27) . Inflammasome activity was monitored by CASP1-dependent processing of pro-IL-1β to p17 in a reconstituted inflammasome system in 5 transfected 293T cells (15, 27) . To our surprise, none of the mutants was auto-active, even though all showed full activity upon cleavage. To test if any N-terminal sequence could mediate auto-inhibition, we replaced the entire N-terminus with a heterologous alpha-helical domain from bacterial flagellin. Again, to our surprise, the hybrid Fla-NLRP1B protein was not autoactive, but was still functional after N-terminal cleavage (Fig. 1D ). Together with prior 10 experiments (19, 27, 28) , these results caused us to reconsider a model in which specific Nterminal sequences of NLRP1B mediate auto-inhibition.
We then asked whether the precise site of N-terminal proteolysis is a major determinant of NLRP1B activation. We generated a series of NLRP1B variants in which a TEV protease cleavage site was positioned at regular intervals from the N-terminus. We found that cleavage of 15 as few as 10 amino acids from the N-terminus was sufficient to activate NLRP1B. Furthermore, there was not a significant correlation between the position of TEV cleavage and NLRP1B activity ( Fig. 1E, F) . In contrast, we noticed a striking negative correlation between the amount of TEV-cleaved NLRP1B protein and inflammasome activation ( Fig. 1E, G ). This correlation, as well as prior evidence that proteasome inhibitors block NLRP1B activity (21) (22) (23) (24) (25) , led us to 20 consider whether proteasome-mediated degradation of NLRP1B is an important step in its activation. Consistent with this idea, we found that the proteasome inhibitors MG132 and Bortezomib not only abrogated NLRP1B activation in our reconstituted 293T system, but also prevented loss of the cleaved NLRP1B protein after LF treatment ( Fig. 2A ). To determine if this loss of cleaved NLRP1B also occurs with the endogenous protein, we derived a monoclonal 25 antibody (2A12) against the C-terminal CARD domain of NLRP1B ( Fig. S1 ). Using this antibody, we could track endogenous NLRP1B in 129S1/SvimJ (129) bone marrow-derived macrophages (BMMs) after treatment with LF ( Fig. 2B ). As observed in the 293T system, LF treatment led to a decrease in NLRP1B, which could be at least partially reversed by MG132 treatment. In contrast, proteasome inhibitors have no effect on NLRP3 (22, 25) or 30 NAIP5/NLRC4 inflammasome activation ( Fig. S2 ), consistent with the hypothesis that the proteasome functions uniquely in NLRP1B inflammasome activation. The precise mechanism by which NLRP1B is targeted to the proteasome after LF cleavage remains unknown. However, the N-end rule pathway is known to recognize cleaved proteins (29, 30) , and N-end rule inhibitors block NLRP1B activation (24). Therefore, we propose that protease cleavage reveals a 35 destabilizing neo-N-terminus that targets NLRP1B for ubiquitylation by N-end rule E3 ubiquitin ligases. Consistent with this hypothesis, in independent and parallel work, the Bachovchin laboratory has recently identified N-end rule ubiquitin ligases that are critical for LF-mediated NLRP1B activation [Chui, A.J. et al (2018) Biorxiv.org].
In the above experiments, the inhibition of NLRP1B activation by proteasome inhibitors 40 might have been due to stabilization of a negative regulator of NLRP1B rather than to stabilization of NLRP1B itself. Therefore, we next asked whether specific degradation of NLRP1B is sufficient to induce its activation. To achieve selective degradation of NLRP1B, the auxin-interacting degron (AID) (31, 32) was fused to the N-terminus of NLRP1B. Upon addition of the auxin hormone indole-3-acetic acid (IAA), the AID recruits a co-expressed TIR1 E3 ligase that specifically ubiquitylates AID-fusion proteins, targeting them to the proteasome. Indeed, IAA induced rapid degradation of the AID-NLRP1B fusion protein and stimulated robust IL-1β processing ( Fig. 2C ). Of note, we found that FIIND auto-processing is also required for IAAinduced activation of AID-NLRP1B ( Fig. 2C ). Degradation and activation were both blocked with proteasome inhibitors (Fig. 2C ) demonstrating that proteasomal degradation of NLRP1B 5 itself is both necessary and sufficient for activation of the NLRP1B inflammasome.
To explain the seemingly paradoxical observation that NLRP1B degradation leads to its activation, we propose the following 'functional degradation' model ( Fig. 3A ). Our proposal relies on the prior observation that FIIND auto-processing is required for activation of NLRP1B by LF. The FIIND domain comprises two separate sub-domains, termed ZU5 and UPA, with 10 auto-processing occurring near the C-terminal end of the ZU5 domain (F983|S984) (18) (19) (20) . After auto-processing, the C-terminal fragment of NLRP1B thus consists of the UPA domain fused to the CARD that is required for CASP1 recruitment and activation. Prior to activation, the FIIND(UPA)-CARD fragment is non-covalently associated with the rest of NLRP1B (Fig. 3A) . After cleavage by LF, NLRP1B is targeted to the proteasome, a processive protease that 15 degrades polypeptides by feeding them through a central barrel (33). Critically, however, directional (N-to C-terminus) and processive degradation of NLRP1B by the proteasome will be interrupted by the covalent break within the auto-processed FIIND domain. At this point, we propose that the C-terminal FIIND(UPA)-CARD fragment is released and is able to seed inflammasome assembly ( Fig. 3A ). 20 Our new 'functional degradation' model of NLRP1B inflammasome activation has several virtues. First, the model explains how N-terminal cleavage results in proteasomedependent NLRP1B activation without a requirement for specific N-terminal 'auto-inhibitory' sequences. Second, the model accounts for why the NLRP1B CARD is C-terminal, rather than N-terminal, as only the C-terminus of NLRP1B remains after proteasome-mediated degradation. 25 Lastly, the model explains why FIIND domain auto-processing is required for NLRP1B activity: an unprocessed FIIND mutant would be fully degraded and would not release a C-terminal CARD-containing fragment.
A strong prediction of the 'functional degradation' model is that the C-terminal FIIND(UPA)-CARD fragment possesses inflammasome activity. Consistent with prior work (20, 30 34), we found that the FIIND(UPA)-CARD fragment was indeed sufficient to promote robust CASP1 activity in our 293T reconstituted inflammasome assay, whereas the full-length FIIND(ZU5+UPA)-CARD remained inactive despite auto-processing ( Fig. 3B ). Likewise, the isolated CARD domain (lacking any portion of the FIIND) was also inactive, implying that the FIIND(UPA) fragment contributes to inflammasome formation. Importantly, the FIIND(UPA)- 35 CARD fragment appears to be a highly potent activator of inflammatory signaling. By titrating the amount of expression construct, we found that the FIIND(UPA)-CARD fragment appeared up to ~150× more potent than TEV-cleavable full-length NLRP1B (Fig. 3C ). These results imply that only a tiny fraction of the total NLRP1B in a cell may need to be degraded to liberate sufficient amounts of the FIIND(UPA)-CARD fragment for robust inflammasome activation. 40 Thus, even if NLRP1B is only degraded half the time in the 'productive' N-to C-terminal direction, this would still likely be sufficient for robust inflammasome activation.
Our 'functional degradation' model predicts that the mature/assembled NLRP1B inflammasome consists solely of the FIIND(UPA)-CARD fragment and CASP1. In support of this hypothesis, only the UPA-containing FIIND-CARD fragment co-immunoprecipitated robustly with CASP1 ( Fig. 3D ) and assembled into higher order oligomers when assessed via non-denaturing PAGE (Fig. 3E ). As such, our model predicts that the NBD and LRR domains of NLRP1B are dispensable for inflammasome activation. Indeed, prior studies found that NBD and LRR mutants of NLRP1B are active, or are even constitutively active (26, 27, 34, 35) , a result 5 that can be explained by the functional degradation model if the mutations destabilize NLRP1B. We further observed that IAA-induced degradation of an AID-FIIND(ZU5+UPA)-CARD fragment is sufficient to induce CASP1 activity ( Fig. 3F ). This result implies that the FIIND-CARD module is sufficient to impart both auto-inhibition and proteasome-induced activation to NLRP1B. While the role of the NBD and LRRs of NLRP1B remains to be determined, we 10 speculate that these domains may contribute to effector recognition.
A major implication of our 'functional degradation' model is that in addition to detecting pathogen-encoded proteases such as LF, NLRP1B can also potentially sense any enzymatic activity that results in NLRP1B degradation. Several pathogens encode E3 ubiquitin ligases that promote virulence through degradation of host target proteins (36). We therefore tested whether 15 the type III secretion system (T3SS)-secreted IpaH family of E3 ubiquitin ligases, encoded by the intracellular bacterial pathogen Shigella flexneri (37-39), are detected by NLRP1B. Using our reconstituted 293T cell system, we found that IpaH7.8, but not IpaH1.4, 4.5 or 9.8, markedly reduced NLRP1B protein levels and induced IL-1β processing in an NLRP1B-dependent manner ( Fig. 4A ). We also noted IpaH4.5 reduced IL-1β levels in cells, but we did not pursue this 20 observation. IpaH7.8 selectively activated the 129 but not the C57BL/6 (B6) allele of NLRP1B ( Fig. 4B ). As expected, FIIND auto-processing was required for IpaH7.8-induced NLRP1B activation ( Fig. 4C ). Truncation of either the IpaH7.8 LRR or E3 domains, as well as mutation of the catalytic cysteine residue (CA) required for E3 ligase activity, also abolished IpaH7.8mediated inflammasome activation ( Fig. 4D ). These results show that IpaH7.8/ubiquitylation-25 dependent degradation of NLRP1B can result in its activation. However, we were unable to detect NLRP1B ubiquitylation. This may be because a small amount of NLRP1B ubiquitylation and degradation is sufficient for its activation, or alternatively, IpaH7.8 may promote NLRP1B degradation indirectly via ubiquitylation of other target proteins in cells.
S. flexneri robustly activates multiple inflammasomes (40) and has previously been 30 reported to cause macrophage cell death in an IpaH7.8-and NLRP1B-dependent manner (41-43), but a connection between IpaH7.8 and NLRP1B has not been established. Consistent with prior studies (41, 43), we found that wild-type S. flexneri induces robust LDH release from infected RAW264.7 macrophages, which is reduced in infections with a ΔipaH7.8 mutant (Fig. 4E ). Cell killing by the ΔipaH7.8 strain complemented with a plasmid expressing ipaH7.8 was greater 35 than even that observed by wild-type bacteria, likely due to effector over-expression. Using CRISPR/Cas9-engineered RAW264.7 cells (44), we found IpaH7.8-dependent cell death is markedly reduced in cells lacking CASP1 or NLRP1B. The NLRC4 inflammasome also recognizes S. flexneri (45-47). In Nlrc4 -/-RAW cells, inflammasome activation was almost entirely IpaH7.8-dependent ( Fig. 4E ). Immortalized 129 macrophages were also sensitive to 40 IpaH7.8-dependent killing, and IpaH7.8 sensitivity correlated with decreased levels of endogenous NLRP1B and the induction of CASP1 maturation (Fig. 4F ). S. flexneri is not a natural pathogen of mice; this may be due in part to species-specific NLRP1B effector recognition as human NLRP1 does not appear to detect IpaH7.8 (data not shown). Taken together, our new mechanistic understanding of NLRP1B has led us to identify ubiquitin ligases as a new category of pathogen-encoded enzyme that activates NLRP1B.
Prior work in Arabidopsis has shown that an NLR called RPS5 detects proteolytic cleavage of the host PBS1 kinase by the translocated Pseudomonas syringae effector AvrPphB (48). In this system, RPS5 appears to detect the cleavage products of PBS1 (49). Although 5 NLRP1B also appears to detect a pathogen-encoded protease, our results suggest that the underlying mechanism is very different than that of RPS5. Instead of proteolysis generating a specific ligand, it appears that NLRP1B is itself the target of proteolysis, leading to its proteasomal degradation, and release of a functional inflammasome fragment. Thus, NLRP1B is in essence a sensor of its own stability, permitting detection of diverse pathogen-encoded 10 enzymes, potentially including those of viruses or parasites (50-52). Although IpaH7.8 and LF protease both activate NLRP1B, we favor a scenario in which the 'intended' targets of these pathogen-encoded enzymes are other host proteins, and that NLRP1B has evolved as a decoy target of these proteins. Although decoy sensors are widely deployed in plant immunity (53), NLRP1 may be the first such sensor described in animals.
15
NLRP1 was the first protein shown to form an inflammasome (10). Our results provide a long-sought mechanism that explains how NLRP1 is activated. Our proposed mechanism may also apply to other FIIND-death domain fold containing proteins, including PIDD1 and CARD8 (18) . In addition to explaining how NLRP1 senses pathogens, our new mechanistic understanding also likely provides an explanation for why naturally occurring mutations that 20 destabilize human NLRP1 (26) also result in its activation. Our results lay the foundation for identifying pathogen-encoded activators of human NLRP1 and provide a conceptual basis for designing therapeutic interventions that target NLRP1. 
Supplementary Materials:

Materials and Methods
Plasmids and constructs
The 129S1/SvimJ (129) Nlrp1b (DQ117584.1) or C57BL/6J (B6) Nlrp1b (BC141354) 35 coding sequence was cloned into either pCMSCV-IRES-GFP or pAcSG2, resulting in Nterminal maltose binding protein (MBP) tag followed by a 3C protease cleavage site and a Cterminal HA or FLAG tag, respectively, or into pQCXIP resulting in N-terminal GFP and Cterminal HA tags. The Fla-NLRP1B hybrid was constructed by replacing the first 45 N-terminal amino acids of NLRP1B with residues 431-475 of Legionella pneumophila Flagellin (ANN95373) followed by the TEV cleavage sequence. CASP1, IL1B, TEV and LF producing constructs were described previously (15). AID (Addgene #80076) and TIR1 (Addgene #80073) producing constructs were a gift from Andrew Holland. The Nlrp1b coding sequence was subcloned in-frame with AID-GFP. GFP-fused IpaH producing plasmids were constructed as follows: the ipaH coding sequences from the S. flexneri 2a str. 2457T virulence plasmid were 5 transferred using the Gateway TM vector conversion system (ThermoFisher) from Gateway entry clones (54) into the SmaI restriction site of the Gateway-compatible destination vector pC1-eGFP (Clontech) via LR reactions. The ipaH7.8 coding sequence was also subcloned into pQCXIP resulting in an N-terminal mCherry tag. For protein expression in E. coli the ipaH coding sequences were subcloned into pET28a with a C-terminal 6X-HIS tag. Mutations were 10 engineered by overlapping PCR.
Cell culture 293T cells were grown in DMEM supplemented with 10% FBS, 100U/ml penicillin, 100mg/ml Streptomycin and 2mM L-glutamine. Primary bone-marrow derived macrophages 15 (BMDMs) were cultured in RPMI supplemented with 5% FBS, 5% mCSF, 100U/ml penicillin, 100mg/ml Streptomycin and 2mM L-glutamine. BMDM immortalization was previously described (55).
Bacterial strains and infections 20 2457T S. flexneri-derived ipaH deletion strains were constructed using the λ red recombinase-mediated recombination system (56), as previously described (57). To construct complemented strains, the coding sequence of ipaH7.8 and 407 basepairs upstream, representing the endogenous promoter, were Gateway cloned into the pCMD136 plasmid and transformed into the ΔipaH7.8 mutant strain. S. flexneri was grown at 37 o C on tryptic soy agar plates 25 containing 0.01% Congo red, supplemented with 100 μg/ml spectinomycin for growth of complemented strains. For infections, 5 ml tryptic soy broth (TSB) was inoculated with a single Congo red-positive colony and grown overnight shaking at 37 o C. Saturated cultures were backdiluted 1:100 in 5 ml fresh TSB and incubated for 2-3 hours shaking at 37 o C. Bacteria were washed in cell culture medium and spun onto cells for 10 minutes at 300xg. Infected cells were 30 incubated at 37 o C for 20 minutes and then washed twice with cell culture medium containing 25μg/ml gentamicin, then returned to 37 o C for further incubation (30 minutes to 2 hours). Cells were infected at an MOI of 30 unless otherwise specified. Cell death was assessed by LDH activity in clarified culture supernatants as previously described (58). Protein in supernatants was TCA precipitated for anti-CASP1 immunoblotting. 35 
Reconstituted NLRP1B activity assays
To reconstitute inflammasome activity in 293T cells, constructs producing NLRP1B (or mutants), CASP1 and IL-1β were co-transfected with constructs producing TEV, LF, IpaHs or empty vector (MSCV2.2 or pcDNA3) using Lipofectamine 2000 (Invitrogen) following the 40 manufacturer's protocol. For experiments using recombinant proteins, fresh media containing 10μg/ml PA and 2.5μg/ml LF, supplemented with or without 10μM MG132 or 1μM Bortezomib, was added to cells for 3-4 hours. For auxin-inducible degradation, AID-NLRP1B and TIR1producing constructs were co-transfected and treated with 500μM indole-3-acetic acid sodium salt (IAA) (Sigma) for 3-6h in the presence or absence of 10μM MG132. In all experiments, cells were lysed in RIPA buffer with protease inhibitor cocktail (Roche) 24 hours posttransfection.
Endogenous NLRP1B activity assays 2.5x10 6 i129 BMDMs were plated in a 6-well plate. 2 hours prior to challenge, cells were 5 primed with 1.0μg/ml Pam3CSK4 (Invivogen). Cells were washed with PBS and media was replaced with 0.5ml Opti-MEM (Gibco) with or without 20μg/ml PA, 10μg/ml LF and/or 10μM MG132. Cells and media were lysed by addition of 120μl of 10X RIPA buffer with protease inhibitor cocktail 2.5 hours post-treatment. 10 Immunoblotting and antibodies Lysates were clarified by spinning at ~16000xg for 10 minutes at 4°C. Clarified lysates were denatured in SDS loading buffer. Samples were separated on NuPAGE Bis-Tris 4-12% gradient gels (ThermoFisher) following the manufacturer's protocol. Gels were transferred onto Immobilon-FL PVDF membranes at 35V for 90 minutes and blocked with Odyssey blocking 15 buffer (Li-Cor). Proteins were detected on a Li-Cor Odyssey Blot Imager using the following primary and secondary antibodies: anti-HA clone 3F10 (Sigma), anti-IL-1β (R&D systems, AF-401-NA), anti-MBP (NEB, E8032S), anti-GFP (Clontech, JL8), anti-mCherry (ThermoFisher, 16D7), anti-CASP1 (Adipogen, AG-20B-0042-C100), anti-Ubiquitin (Cell Signaling, P4D1), Alexfluor-680 conjugated secondary antibodies (Invitrogen). 20 To produce the mouse anti-NLRP1B monoclonal antibody, the pAcSG2-Nlrp1b construct was co-transfected with BestBac linearized baculovirus DNA (Expression Systems) into SF9 cells following the manufacturer's protocol to generate NLRP1B expressing baculovirus. Primary virus was amplified in SF9 cells. NLRP1B was produced by infecting 4L of High Five cells with 1ml of amplified virus/L cells. Cells were harvested 48 hours after infection by 25 centrifugation at 300xg for 15 minutes. Cell pellets were resuspended in lysis buffer (50mM Hepes pH7.5, 150mM NaCl, 1% NP-40, 5% glycerol) and lysed on ice using a dounce homogenizer. Homogenized samples were clarified at 24000xg for 30 minutes and supernatants were batch bound to 1ml amylose resin for 2 hours at 4 o C. Samples were column purified by gravity. Resin was washed with 50ml of wash buffer (20mM Hepes pH7.4, 150mM NaCl, 0.02% 30 NP-50, 5% glycerol). Sample was eluted with 1ml fractions of elution buffer (20mM Hepes pH7.4, 150mM NaCl, 0.02% NP-50, 5% glycerol, 20mM Maltose). Peak elutions were pooled and MBP was cleaved by treatment overnight with 3C protease. Free MBP was removed by passing sample amylose resin. BALB/c mice were immunized with 10μg NLRP1B plus 100μl Sigma adjuvant four times. Splenocytes were fused the with the P3X63-Ag8.653 parental line. 35 Clones were screened via ELISA against recombinant NLRP1B protein or recombinant FLAGtagged MBP protein to identify clones specifically reactive to NLRP1B. Clarified supernatant from the hybridoma clone 2A12 was used for immunoblotting.
Native gel oligomerization assay 40 Samples were transfected into 293T cells with constructs as above in a 6-well plate. After 24 hours, samples were harvested by removing media and washing cells off plate with cold PBS. Harvested cells were centrifuged at 300xg for 10 minutes at 4 o C. Cells were lysed in lysis buffer (50mM Hepes pH7.5, 150mM NaCl, 1% NP-40, 5% glycerol) and samples were clarified by spinning at 16000xg for 10 minutes at 4 o C. Samples were run on NativePAGE Bis-Tris gels (ThermoFisher) according to manufacturer's protocols. Fig. S3 (Fig. 3) The FIIND(UPA)-CARD fragment is a potent activator of IL1β processing. 
